Powder: -20°C for 3 years | In solvent: -80°C for 1 year
GNE-493 是选择性的PI3K/mTOR 抑制剂,能够抑制 PI3Kα (IC50:3.4 nM),PI3Kβ (IC50:12 nM),PI3Kδ (IC50:16 nM),PI3Kγ (IC50:16 nM) 和 mTOR (IC50:32 nM)。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 937 | 现货 | ||
2 mg | ¥ 1,430 | 现货 | ||
5 mg | ¥ 2,420 | 现货 | ||
10 mg | ¥ 3,160 | 现货 | ||
25 mg | ¥ 4,970 | 现货 | ||
50 mg | ¥ 6,870 | 现货 | ||
100 mg | ¥ 9,450 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 2,670 | 现货 |
产品描述 | GNE-493 is potent, selective, and orally available PI3K and mTOR inhibitor with potential anticancer activity.IC50s of 3.4 nM, 12 nM, 16 nM, 16 nM and 32 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ and mTOR,respectively. |
靶点活性 | mTOR:32 nM, PI3Kγ:16 nM , PI3Kα:3.4 nM , PI3Kβ:12 nM , PI3Kδ:16 nM |
体内活性 | GNE-493 is examined in the human MCF7.1 breast cancer xenograft model that harbors a PI3Kα activating mutation. Mice bearing xenografts are dosed orally once daily with 10 mg/kg of GNE-493 for 21 continuous days. Similar to observations made in the PC3 prostate cancer xenograft model, 10 mg/kg of GNE-493 results in 73% tumor growth inhibition at day 21 when compared to vehicle control animals. When achieving comparable levels of drug exposure, GNE-493 shows a similar suppression of the PI3K pathway and consequently, a similar efficacy profile against MCF7.1 breast tumors |
分子量 | 372.44 |
分子式 | C17H20N6O2S |
CAS No. | 1033735-94-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 45 mg/mL (120.82 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.685 mL | 13.425 mL | 26.85 mL | 67.1249 mL |
5 mM | 0.537 mL | 2.685 mL | 5.37 mL | 13.425 mL | |
10 mM | 0.2685 mL | 1.3425 mL | 2.685 mL | 6.7125 mL | |
20 mM | 0.1342 mL | 0.6712 mL | 1.3425 mL | 3.3562 mL | |
50 mM | 0.0537 mL | 0.2685 mL | 0.537 mL | 1.3425 mL | |
100 mM | 0.0268 mL | 0.1342 mL | 0.2685 mL | 0.6712 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
GNE-493 1033735-94-2 PI3K/Akt/mTOR signaling PI3K mTOR Mammalian target of Rapamycin GNE493 Inhibitor inhibit Phosphoinositide 3-kinase GNE 493 inhibitor